Journal of Clinical Oncology
Articles in this Issue
Multi-omics cohort-based prediction model for early relapse of hepatocellular carcinoma post-surgery.
3137 Background: Postoperative early relapse (PER) of hepatocellular carcinoma (HCC) presents significant challenges in clinical management. Identifying r...
Incidence and treatment outcomes of small cell carcinoma of the small intestine, colon, and rectum.
e15682 Background: Small cell carcinoma (SCC) of gastrointestinal tract is a highly aggressive rare malignancy with an estimated prevalence of 0.1% to 1%...
Dissecting racial, socioeconomic, and treatment disparities in peripheral T-cell lymphoma: A comprehensive Surveillance, Epidemiology, and End Results–based retrospective analysis.
e19086 Background: Peripheral T-cell lymphomas (PTCLs) are aggressive and heterogeneous lymphomas with poor outcomes. The aim of this study was to evaluat...
Estrogen receptor (ER) expression on circulating tumor cells (CTCs) and cell free DNA (cfDNA) mutational landscape in the PACE randomized phase II study.
1054 Background: The PACE (NCT03147287) randomized phase II trial investigates CDK4/6 inhibition beyond progression in combination with endocrine treatmen...
Real-word research on the effect and safety of gemcitabine combined with PD-1 inhibitors and recombinant human endostatin in refractory recurrent nasopharyngeal carcinoma.
e18016 Background: Recurrent nasopharyngeal carcinoma (rNPC) exhibits high heterogeneity, and conventional treatments often yield limited efficacy with si...
Early insights into the impact of an ambient AI scribe solution on clinical documentation to reduce clinician burnout in oncology.
e13722 Background: Documentation burden can cause clinician burnout leading to poor decision making, patient safety events and clinician turnover. Innovat...
AI-driven digital platforms accelerate education and adoption of newly implemented treatment guideline recommendations.
e13671 Background: Advances in Research continually drive improvements in patient care, with numerous breakthroughs driving updates to clinical guidelines...
First results of an open-label, single arm phase II trial investigating the efficacy and safety of trifluridine/tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma.
4121 Background: Cholangiocarcinoma (CCA) is a rare and aggressive malignancy with poor prognosis. Although firstline therapy with gemcitabine, cisplatin...
Systemic immune-inflammation index as a survival predictor in advanced urothelial carcinoma treated with avelumab maintenance.
e16559 Background: Systemic immune-inflammation index (SII) is a predictor of survival in patients with various malignancies. This analysis was performed...
Real-world study on first-line immunochemotherapy in advanced gastric/gastroesophageal junction cancer (GC/GEJC): Predicting response with peripheral immune landscape.
e16023 Background: Immunocheckpoint inhibitors combined with chemotherapy have become the standard first-line treatment for advanced GC/GEJC. Nevertheless...
Effect of bacterial glycosyltransferases on resistance to Lewis Y-targeting antibody-drug conjugates.
e15013 Background: Bacteria in the tumour microenvironment (TME) influence anticancer drug pharmacodynamics, potentially contributing to variability in cl...
Real-world evaluation of the reduction in complexity of ordering DNA sequencing tests through the adoption of Fast Healthcare Interoperability Resources (FHIR) standards.
e13719 Background: The automated transfer of ordering information and the return of discrete molecular data from pathology labs into the electronic health...
Phase 3 trial of adjuvant cemiplimab (cemi) versus placebo (pbo) for high-risk cutaneous squamous cell carcinoma (CSCC).
6001 Background: Cemiplimab is standard of care for treatment of patients (pts) with advanced (metastatic/unresectable) CSCC. There is no approved systemi...
Equity analysis of clinical oncology treatment pathways usage in an integrated health care delivery system.
e13760 Background: Oncology treatment has been rapidly evolving and becoming increasingly complex. At Kaiser Permanente (KP), we created a decision suppor...
Understanding glioblastoma survival: A SEER-based study of demographics and treatment.
e14027 Background: Glioblastoma is an aggressive brain tumor characterized by rapid progression, high recurrence, and poor survival. Prognosis is influenc...
Gastroesophageal reflux disease and upper aerodigestive tract cancer risk: A meta-analysis of site-specific associations.
e18106 Background: Gastroesophageal reflux disease (GERD), which affects approximately 20% of the U.S. population, has been implicated as a potential risk...
Impact of adjuvant systemic cancer therapies on health-related quality of life: A systematic review of randomized controlled trials.
e23200 Background: Adjuvant systemic treatments reduce the risk of cancer recurrence and can improve survival in various cancer types. However, adverse ev...
Avelumab maintenance therapy in patients (pts) with advanced urothelial carcinoma (UC) in Japan: Subgroup analyses by best overall response (BOR) to prior platinum-based chemotherapy (PBC) in a post-marketing surveillance (PMS) population.
4561 Background: Avelumab was approved as maintenance therapy for pts with advanced UC that has not progressed after first-line PBC based on results from...
Exploring the mutational and molecular profile of pancreatic cancer: A comprehensive genomics approach.
e16417 Background: Pancreatic cancer is an aggressive and often fatal malignancy, with its asymptomatic nature complicating diagnosis and treatment. Thera...
Phase 1 study of DK2 <sup>10</sup> (EGFR), a tumor-targeted IL2 x IL10 dual immunocytokine, in advanced cancer patients: Dose escalation, immune activation, and safety results.
2589 Background: IL-2 induces anti-tumor immunity and toxicity, predominantly vascular leak syndrome (VLS), leading to edema, hypotension, organ toxicity,...
Independent effects of comorbidities and race on breast cancer mortality.
e13791 Background: Racial disparities and breast cancer outcomes are well-documented. Socioeconomic inequalities, diagnostic delays, and comorbid conditio...
Impact of lorlatinib dose modifications on adverse event outcomes in the phase 3 CROWN study.
8590 Background: In an updated analysis of the CROWN study (NCT03052608), after 5 years of follow-up, lorlatinib continued to show superior efficacy over...
The impact of adjuvant endocrine therapy on outcomes in estrogen receptor-low positive breast cancer patients.
e12516 Background: Estrogen Receptor (ER)-low positive breast cancer, defined as ER expression of 1-10% by immunohistochemistry, is a rare subtype with mo...
Low-dose radiotherapy combined with neoadjuvant chemotherapy and an anti-PD-1/CTLA-4 bispecific antibody cardonilizumab for resectable locally advanced head and neck squamous cell carcinoma: Preliminary report of a single-arm, prospective phase II clinical study.
e18026 Background: About 70% ~ 80% of head and Neck Squamous Cell Carcinoma (HNSCC) patients are locally advanced (stage III-IVB) at the time of initial d...
Role of p57 in cGAS-STING-mediated innate sensing and immunotherapy response in hepatocellular carcinoma.
2585 Background: Hyperactivation of cell cycle programs in cancer cells suppresses the antitumor immune response. The endogenous cyclin-dependent kinase i...